GIP and GLP-1 receptor agonist
Tirzepatide
A dual GIP and GLP-1 receptor agonist with approved products and large human trials, bounded by product-specific indications, labels, and safety information.
Also known as Mounjaro · Zepbound · GIP/GLP-1 agonist
01 · Evidence profile
One molecule, four evidence questions
Large randomized programs support defined glycemic and chronic weight-management outcomes.
Pharmacology and exposure are extensively characterized for approved products.
Current product labels describe boxed warnings, contraindications, precautions, and adverse reactions.
High for an authentic approved product; not transferable to every compounded or counterfeit version.
02 · Identity
What it is
Tirzepatide is a modified peptide used as the active ingredient in prescription medicines. Approval belongs to a specific product, indication, formulation, and current label, not to every item marketed with the same ingredient name.
03 · Product identity
The molecule is not the finished product.
Mounjaro and Zepbound are distinct approved products. Their evidence and labels do not make every compounded or research-labeled tirzepatide product equivalent.
Mounjaro
2026 label- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Type 2 diabetes uses and populations defined in the current Mounjaro label.
Zepbound
2026 label- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Chronic weight management and obstructive sleep apnea uses and populations defined in the current Zepbound label.
- Mounjaro
- Zepbound
- Type 2 diabetes for labeled populations
- Chronic weight management for labeled populations
- Obstructive sleep apnea indication described in the current Zepbound label
04 · Evidence snapshot
What the evidence can and cannot say
FDA-reviewed labels and large randomized trials support glycemic and weight outcomes in defined populations. SURPASS-2 studied adults with type 2 diabetes, while SURMOUNT-1 studied adults with obesity or overweight and a related complication without diabetes. Those populations, comparators, endpoints, and study durations define the result.
The evidence does not show that tirzepatide produces the same result for everyone, acts as a universal “metabolic reset,” or establishes longevity or athletic-performance benefits. It also does not make compounded, counterfeit, or research-labeled products equivalent to approved medicines.
05 · Claim check
Three claims under the lens
“Tirzepatide has established human outcome evidence for defined metabolic indications.”
Approved product labels and large randomized trials support specific glycemic and weight outcomes in defined populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Mounjaro and Zepbound in the labeled and trial populations, endpoints, comparators, and durations.
“Trial results prove tirzepatide works the same way for everyone and should be used indefinitely.”
Trials estimate effects for studied populations and durations. They do not establish an identical individual response or a universal treatment duration.
- Evidence basis
- Randomized human outcomes
- Scope
- The defined populations and follow-up durations in SURMOUNT-1 and SURPASS-2.
“Compounded tirzepatide is equivalent to an approved product.”
FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, so evidence for an approved product cannot simply be transferred.
- Evidence basis
- Regulatory or product record
- Scope
- Compounded or otherwise unapproved tirzepatide compared with approved Mounjaro or Zepbound.
06 · Safety boundary
Before this becomes personal
Current prescribing information contains a boxed warning and important contraindications, warnings, and precautions. This guide does not decide eligibility, recommend a product, or provide titration or dosing instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Expanded product, outcome, and unapproved-version boundaries.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.